Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Visit Lily AI at the 2025 NRF Big Show to experience firsthand how our AI-powered product attributes platform is transforming Google advertising for retail, and shopping search and discovery. The team ...

The centre, will initially focus on expanding Lilly's capabilities in automation, artificial intelligence, software product ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...

Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and ...